Marinomed licenses nasal spray targeting common cold to Boehringer in certain territories
This article was originally published in Scrip
Executive Summary
Marinomed Biotechnologie has signed a licensing agreement aimed at expanding the commercialisation of its antiviral nasal spray for the treatment of the common cold with Boehringer Ingelheim. The agreement covers all of Europe (excluding Austria and the UK), Russia and the ex-Soviet republics, South America, parts of Asia and Australia.